CN114231446B - 鼠李糖乳杆菌lrx-01的应用 - Google Patents
鼠李糖乳杆菌lrx-01的应用 Download PDFInfo
- Publication number
- CN114231446B CN114231446B CN202111449823.9A CN202111449823A CN114231446B CN 114231446 B CN114231446 B CN 114231446B CN 202111449823 A CN202111449823 A CN 202111449823A CN 114231446 B CN114231446 B CN 114231446B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- lrx
- high temperature
- mice
- caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 62
- 230000008642 heat stress Effects 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 31
- 230000004083 survival effect Effects 0.000 abstract description 13
- 239000002158 endotoxin Substances 0.000 abstract description 9
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000002757 inflammatory effect Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 238000002203 pretreatment Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 206010019345 Heat stroke Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 210000004907 gland Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000009631 Broth culture Methods 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- ZDUOUNIIAGIPSD-UHFFFAOYSA-N 1,1,1-tribromoethane Chemical compound CC(Br)(Br)Br ZDUOUNIIAGIPSD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX‑01在制备防治高温引起的人或哺乳动物的疾病的产品中的应用,本发明的发明人在对小鼠进行热应激试验时发现,经鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX‑01预处理,可以明显延长高温处理小鼠的生存时间,降低其血清炎症因子和内毒素,减轻热应激导致的肠道损伤,这些结果表明,鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX‑01在预防和治疗由高温引起的人或哺乳动物的疾病方面具有潜在的应用价值。
Description
技术领域
本发明属于生物技术领域,特别是涉及一株鼠李糖乳杆菌
Lactobacillus
rhamnosusLRX-01在制备防治高温引起的人或哺乳动物的疾病的产品中的应用。
背景技术
高温可导致热应激(heat stress,HS)、中暑(heatstroke)或精神性神经障碍。HS是机体在高温环境下所经历的一种应激反应,当体内增热率高于散热率时,就会出现体温过高,当体温升高到40.5℃临界水平时导致中暑,其特征是中枢神经***损伤和多器官衰竭。由于全球气温的升高、城市环境的扩张和寿命的延长,死于中暑的人数开始增加,中暑已然成为威胁生命的健康问题。有效地干预和控制高温引起的疾病,从而预防中暑以及降低其它高温相关性疾病的发生率已经是全球公共卫生需要。
高温致死的重要原因之一是肠粘膜屏障功能受损后发生的肠源性内毒素易位,同时由于发生了肠源性内毒素血症,从而显著促进了***性炎症反应和多器官功能障碍的进展,所以预防肠粘膜屏障的损伤可能是中暑患者的有效的预防和治疗方式。阿司匹林和扑热息痛等抗炎药对中暑有一定的作用,但因为这两种药分别会加重凝血功能和肝损伤,存在潜在危害,而及时缓解热应激引起的肠道屏障功能障碍,可以逆转***性炎症反应、弥散性血管内凝血和多器官功能障碍所致的高死亡率。
鼠李糖乳杆菌为乳杆菌属、鼠李糖杆菌种,是无质粒、厌氧耐酸、不产芽孢的革兰氏阳性菌,大多存在于人和动物肠道内,具有耐酸、耐胆汁盐、耐多种抗生素等生物学特点。鼠李糖乳杆菌能耐受宿主消化道环境,肠道黏着率高,定植于宿主肠道内调节肠道菌群,有降低胆固醇、排除毒素、预防龋齿和增强免疫力等作用,已成为国际上文献记载最多和应用最广的益生菌之一。有大量的实验表明,鼠李糖乳杆菌可预防抗生素引起的腹泻,并使疾病相关的腹泻得以恢复,还可提高免疫功能从而具备抗致病性活性。但是鼠李糖乳杆菌在防治高温导致的疾病中尚无报道。
发明内容
基于此,本发明的目的之一是提供鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01在制备防治高温引起的疾病的产品中的应用。
实现上述发明目的的具体技术方案包括如下:
鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01在制备防治高温引起的人或哺乳动物的疾病的产品中的应用,该鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:60986。
本发明还提供了上述鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01的培养物在制备防治高温引起的人或哺乳动物的疾病的产品中的应用。
本发明还提供了上述鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01的代谢产物在制备防治高温引起的人或哺乳动物的疾病的产品中的应用。
在其中一些实施例中,所述高温引起的疾病为热应激、中暑、精神性神经障碍、或全身性炎症。
在其中一些实施例中,所述产品为药品、菌剂或饲料添加剂。
在其中一些实施例中,所述产品为药品,所述药品还包括药学上可接受的辅剂,所述辅剂为稳定剂、湿润剂、乳化剂、粘合剂、等渗剂中的一种或几种。
在其中一些实施例中,所述药品的剂型为片剂、颗粒剂、散剂、胶囊剂、溶液剂、悬浮剂、或冻干制剂。
与现有技术相比,本发明具有以下有益效果:
本发明的发明人在对小鼠进行热应激试验时发现,经鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01预处理,可以明显延长高温处理小鼠的生存时间,降低其血清炎症因子和内毒素,减轻热应激导致的肠道损伤,这些结果表明,鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01在预防和治疗由高温引起的人或哺乳动物的疾病方面具有潜在的应用价值。
附图说明
图1是实施例1中分离得到的鼠李糖乳杆菌LRX-01革兰氏染色结果。
图2是实施例1中分离得到的鼠李糖乳杆菌LRX-01的16S rDNA***进化发育树。
图3是实施例1中分离得到的鼠李糖乳杆菌LRX-01糖酵解生化试验结果。
图4是实施例4中气相色谱—质谱检测鼠李糖乳杆菌LRX-01的短链脂肪酸结果。
图5是实施例5中鼠李糖乳杆菌LRX-01延长高温处理小鼠生存的实验结果。
图6是实施例6中鼠李糖乳杆菌LRX-01延长高温处理小鼠生存时减少HS后血清炎症因子和内毒素释放的实验结果。
图7是实施例6中鼠李糖乳杆菌LRX-01延长高温处理小鼠生存时肠组织病理切片图。
具体实施方式
本发明下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂,均为市售产品。
除非另有定义,本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不用于限制本发明。
本发明所述的鼠李糖乳杆菌LRX-01,分类命名为
Lactobacillus rhamnosus,已于2020年3月26日保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:60986,保藏单位地址:广州市先烈中路100号大院59号楼5楼广东省微生物研究所。
在本发明中,所述高温为自然环境中的高温,当人体或哺乳动物处于高温环境时,人的生理功能,尤其是体温调节、水盐代谢、血液循环等功能将会出现开始为生理适应,之后到功能紊乱的异常改变,如大量出汗,心血管负担加重等。若高温超过人体的耐受力,最常见的表现是中暑。中暑是由于高温环境下,发生热平衡和/或水盐代谢紊乱等,而引起的一种以中枢神经***和/或心血管***障碍为主要表现的急性热致疾病。
鼠李糖乳杆菌(
Lactobacillus rhamnosus)是益生菌的一种,目前已被纳入***下发的《可用于食品的菌种名单》,本发明的鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01益生菌是从健康新生儿粪便中分离出的乳杆菌属的另一种亚型,可见,有效成分为鼠李糖乳杆菌(
Lactobacillus rhamnosus)LRX-01的产品在治疗过程中不会导致患者产生不良反应。
下述实施例中涉及的鼠李糖乳杆菌标准株ATCC 53103(即鼠李糖乳杆菌LGG),来源于美国模式培养物集存库(ATCC),保藏编号为ATCC 53103。
下述实施例中涉及的培养基如下:
MRS固体培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠5g/L、酵母提取物5g/L、柠檬酸氢二铵2g/L、K2HPO42g/L、MgSO4•7H2O 0.58g/L、MnSO40.05 g/L、吐温80 1mL/L、琼脂15g/L~17g/L,pH6.12~6.2。
MRS肉汤培养基(g/L):蛋白胨10g/L、牛肉膏10g/L、葡萄糖20g/L、乙酸钠5g/L、酵母提取物5g/L、柠檬酸氢二铵2g/L、K2HPO42g/L、MgSO4•7H2O 0.58g/L、MnSO40.05 g/L、吐温80 1mL/L,pH6.12~6.2。
以下结合具体实施例和附图对本发明进行进一步说明。
实施例1鼠李糖乳杆菌LRX-01的分离鉴定
1、鼠李糖乳杆菌LRX-01的分离
包括以下步骤:
(1)、收集纯母乳喂养的健康新生儿新鲜粪便,按固液比为1:1000(g/ml)的比例加入PBS稀释;
(2)、取5μl稀释后的样本涂布于MRS固体培养基,37℃ 恒温厌氧培养48 h;
(3)、根据菌落的颜色、大小、边缘形状等,用接种环挑取菌落,划线纯化;
(4)、挑取单菌落,接种至MRS液体培养基,增菌培养,即得。
2、菌株的形态学特征
菌落特征:菌落生长良好,为乳白色,圆型,凸起,边缘整齐。
菌体特征:短小的杆状,不运动,无芽孢,兼性厌氧,革兰氏染色阳性(如图1所示)。
3、菌株的分子生物学鉴定
用细菌基因组DNA试剂盒(TIANamp Bacteria DNA Kit)提取细菌总DNA,提取方法步骤根据试剂盒说明书进行。使用乳酸菌16S rDNA的通用引物(引物由上海生工生物有限公司合成)对提取的DNA进行PCR扩增。
16S rDNA的通用引物对核苷酸序列为:
正向引物27f:5'-AGAGTTTGATCCTGGCTCAG-3'(SEQ ID NO:1)
反向引物1492r:5'-GGTTACCTTGTTACGACTT-3'(SEQ ID NO:2)
PCR扩增反应体系共20μl,DNA模板2μl,TaKaRa Premix TaqTM 10 μl,正向引物、反向引物各1μl,dd H2O 6μl。阴性对照(control)反应体系中,模板以ddH2O代替,其余成分一样。
PCR扩增反应条件:94℃ 5 min;94℃ 60 s,60℃ 60 s,72℃ 90 s,30 个循环;72℃ 10 min;4℃ 保存。
PCR电泳后进行切胶,回收目的条带凝胶并由上海生工生物有限公司测序。在美国NCBI数据库,应用BLAST软件工具对菌株16S rDNA基因序列进行比对,并用MEGAX构建***发育树。
结果如图2所示,从图2可以看出,本实施例中分离得到的菌株的测序结果,与鼠李糖乳杆菌的16S rDNA序列同源性达到99%,鉴定本实施例中分离得到的菌株属于鼠李糖乳杆菌
Lactobacillus rhamnosus,命名为LRX-01。核苷酸序列如SEQ ID No:3所示。
GCGGGGCGGGTGCTATACATGCAGTCGAACGAGTTCTGATTATTGAAAGGTGCTTGCATCTTGATTTAATTTTGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGCAATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGTGCATCGGAAACTGGRAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTAGGGAGCGAGCCGTCTAAGGTGAACAAAA(SEQ ID NO:3)
4、糖发酵实验进行菌株鉴定
利用糖发酵实验对菌株进行鉴定,根据新型微生物微量生化系列鉴定管说明书进行操作,检测本实施例分离所得的菌株LRX-01的生化代谢物。结果如表1和图3所示。从表1和图3可知,该菌种的生理生化特征与鼠李糖乳杆菌标准株ATCC53103的生理生化性质基本一致。
表1本实施例分离得到的菌株的生化鉴定结果
注:“+”为反应阳性,“-”为反应阴性。
综上,根据形态学特征、分子生物学鉴定和糖发酵实验结果,将本发明实施例1中分离筛选到的菌株鉴定为鼠李糖乳杆菌,该菌株于2020年03月26日保藏于广东省微生物菌种保藏中心,分类命名为:
Lactobacillus rhamnosusLRX-01,保藏编号为GDMCC No:60986。
实施例2 本发明的鼠李糖乳杆菌LRX-01对人工胃液的耐受作用试验
分别配制pH值为2.0,3.0,4.0 的人工胃液。分别取鼠李糖乳杆菌标准株ATCC53103和本发明的鼠李糖乳杆菌LRX-01,用无菌PBS稀释为109CFU/ml的菌悬液。吸取菌悬液10μl于990μl不同pH值的人工胃液中,37℃ 厌氧培养1h~3h,使用稀释滴板法测定初始与培养后的活菌数。结果如表2所示。
表2 ATCC53103与LRX-01耐受人工胃液性能比较
从表2可知,与鼠李糖乳杆菌标准株ATCC 53103相比,本发明的鼠李糖乳杆菌LRX-01表现出更好的耐人工胃液能力。
实施例3 本发明的鼠李糖乳杆菌LRX-01产短链脂肪酸的能力测试
分别配制如下待测溶液:
(1)、取调至OD600=1的鼠李糖乳杆菌LRX-01菌液100μl加到8ml MRS肉汤培养基中培养24h,取菌悬液1mL于1.5mL离心管,10000rpm/min离心2min,取上清100μl,加入5μl内标(IS),5μl去离子水,150μl甲醇,40μl 2.5% H2SO4,0.05g无水硫酸钠,涡旋1.5min,离心(14000rpm,室温,5min);取上清于装有衬管的进样小瓶,待测。
(2)、取调至OD600=1的鼠李糖乳杆菌标准株ATCC53103菌液100μl加到8ml MRS肉汤培养基中培养24h,取菌悬液1mL于1.5mL离心管,10000rpm/min离心2min,取上清100μl,加入5μl内标(IS),5μl去离子水,150μl甲醇,40μl 2.5% H2SO4,0.05g无水硫酸钠,涡旋1.5min,离心(14000rpm,室温,5min);取上清于装有衬管的进样小瓶,待测。
(3)、配制随行空白样本:取100μl生理盐水,加入5μl内标(IS),5μl去离子水,150μl甲醇,40μl 2.5% H2SO4,0.05g无水硫酸钠,涡旋1.5min,离心(14000rpm,室温,5min),取上清于装有衬管的进样小瓶,待测。
(4)、配制质控样本:取100μl生理盐水,加入5μl内标(IS),5μl STD -4,150μl甲醇,40μl 2.5% H2SO4,0.05g无水硫酸钠,涡旋1.5min,离心(14000rpm,室温,5min),取上清于装有衬管的进样小瓶,待测。
气相色谱-质谱(GC-MS)测定上述(1)-(4)各处理中的短链脂肪酸含量。
结果如图4所示,从图4可以看出,与鼠李糖乳杆菌标准株ATCC53103相比,本发明的鼠李糖乳杆菌LRX-01表现出更好的产短链脂肪酸能力,短链脂肪酸总量更高,尤其丙酸、丁酸、庚酸产量较高。
实施例4本发明的鼠李糖乳杆菌LRX-01对高温处理小鼠生存的保护作用
本实施例研究了鼠李糖乳杆菌LRX-01对高温处理小鼠生存的保护作用,具体包括以下步骤:
(1)、4周龄C57BL/6小鼠32只,正常饲养两周后随机分成4组:室温对照组(CON,n=8)、室温鼠李糖乳杆菌预处理组(LRX-01,n=8)、高温致热应激对照组(HS)、高温致热应激鼠李糖乳杆菌预处理组(LRX-01+HS,n=8)。
(2)、每天固定晚上7点,CON和HS组予以200μl无菌PBS溶液灌胃处理,LRX-01和LRX-01+HS组小鼠,予以鼠李糖乳杆菌(200μl,1×108CFU,PBS溶液重悬)灌胃,均处理2周,至少每2天观察一次,判断有无死亡,体型差异是否过大。
(3)、处理两周后,小鼠迅速转入湿度(75±5%),温度(42±0.5℃)高温仓进行HS实验。整个HS过程不给食物和饮水,每隔20min记录一次肛温,并注意观察小鼠的一般情况、精神状态和死亡情况,直至所有小鼠死亡截止。
结果图5所示。
从图5可以看出,CON和LRX-01组在观察期内小鼠全部存活,而HS组在2h的观察期内全部死亡,中位生存时间为1.58h,平均生存时间1.59h;LRX-01+HS组中位生存时间是1.63h,平均生存时间9.9h。与HS组相比,LRX-01+HS组小鼠中位生存时间和平均生存时间明显增加(p<0.05),差异具有统计学意义,说明LRX-01预处理可以延长HS小鼠的生存时间。
实施例5 本发明的鼠李糖乳杆菌LRX-01对高温处理小鼠炎症的缓解作用
本实施例研究了鼠李糖乳杆菌LRX-01对高温处理小鼠炎症的缓解作用,具体包括以下步骤:
(1)、4周龄C57BL/6小鼠32只,正常饲养两周周后随机分成4组:室温对照组(CON,n=8)、室温鼠李糖乳杆菌预处理组(LRX-01,n=8)、高温致热应激对照组(HS)、高温致热应激鼠李糖乳杆菌预处理组(LRX-01+HS,n=8)。
(2)、每天固定晚上7点,CON和HS组予以200μl无菌PBS溶液灌胃处理,LRX-01和LRX-01+HS组小鼠予以鼠李糖乳杆菌(200μl,1×108CFU,PBS溶液重悬)灌胃,均处理2周,至少每2天观察一次,判断有无死亡,体型差异是否过大。
(3)、处理两周后,小鼠迅速转入湿度(65±5%),温度(41±0.5℃)高温仓进行HS实验。整个HS过程不给食物和饮水,每隔20min记录一次肛温,并注意观察小鼠的一般情况、精神状态和死亡情况,待到对照组小鼠肛温基本达到42℃时,立即出仓,注意保温,恢复食物和饮水,密切观察小鼠情况。
(4)、出仓4h后,给予小鼠三溴乙烷(2mg/kg)腹腔注射进行麻醉,摘取眼球法取血后处死小鼠。手术剪剪开腹膜,解剖出回盲部以下5cm肠段,液氮速冻后置于-80℃冰箱,结肠一部分液氮速冻,一部分用4%多聚甲醛固定48小时后包埋切片。
各组小鼠全血的炎症因子和内毒素检测结果如图6所示,从图6可以看出:HS条件下小鼠TNF-α和IL-β水平明显升高,LRX-01+HS组炎症因子TNF-α和IL-β较HS组有显著减缓,各组之间IL-6的水平没有显著性差异。HS组内毒素较CON组显著升高,LRX-01+HS组内毒素水平显著低于HS组,LRX-01组血清中内毒素含量最低,差异具有统计学意义(p<0.05)。说明鼠李糖乳杆菌LRX-01预处理可一定程度上减缓内毒素释放和全身炎症反应。
各组小鼠肠道组织的HE染色结果如图7所示,图7显示: CON组小鼠肠道粘膜腺体正常,结构规则,开口良好;LRX-01组腺体正常,结构良好;HS组小鼠结肠腺体结构紊乱,腺体肿胀,炎症细胞浸润,分叶状细胞增多;LRX-01+HS组腺体肿胀仅局限于肠上皮,腺体排列较整齐,有部分炎症细胞浸润。说明鼠李糖乳杆菌LRX-01预处理可以减轻HS导致的肠道损伤。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
序列表
<110> 南方医科大学 广州维生君生物科技有限公司
<120> 鼠李糖乳杆菌LRX-01的应用
<130> 1
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
agagtttgat cctggctcag 20
<210> 2
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
ggttaccttg ttacgactt 19
<210> 3
<211> 1471
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
gcggggcggg tgctatacat gcagtcgaac gagttctgat tattgaaagg tgcttgcatc 60
ttgatttaat tttgaacgag tggcggacgg gtgagtaaca cgtgggtaac ctgcccttaa 120
gtgggggata acatttggaa acagatgcta ataccgcata aatccaagaa ccgcatggtt 180
cttggctgaa agatggcgta agctatcgct tttggatgga cccgcggcgt attagctagt 240
tggtgaggta acggctcacc aaggcaatga tacgtagccg aactgagagg ttgatcggcc 300
acattgggac tgagacacgg cccaaactcc tacgggaggc agcagtaggg aatcttccac 360
aatggacgca agtctgatgg agcaacgccg cgtgagtgaa gaaggctttc gggtcgtaaa 420
actctgttgt tggagaagaa tggtcggcag agtaactgtt gtcggcgtga cggtatccaa 480
ccagaaagcc acggctaact acgtgccagc agccgcggta atacgtaggt ggcaagcgtt 540
atccggattt attgggcgta aagcgagcgc aggcggtttt ttaagtctga tgtgaaagcc 600
ctcggcttaa ccgaggaagt gcatcggaaa ctggraaact tgagtgcaga agaggacagt 660
ggaactccat gtgtagcggt gaaatgcgta gatatatgga agaacaccag tggcgaaggc 720
ggctgtctgg tctgtaactg acgctgaggc tcgaaagcat gggtagcgaa caggattaga 780
taccctggta gtccatgccg taaacgatga atgctaggtg ttggagggtt tccgcccttc 840
agtgccgcag ctaacgcatt aagcattccg cctggggagt acgaccgcaa ggttgaaact 900
caaaggaatt gacgggggcc cgcacaagcg gtggagcatg tggtttaatt cgaagcaacg 960
cgaagaacct taccaggtct tgacatcttt tgatcacctg agagatcagg tttccccttc 1020
gggggcaaaa tgacaggtgg tgcatggttg tcgtcagctc gtgtcgtgag atgttgggtt 1080
aagtcccgca acgagcgcaa cccttatgac tagttgccag catttagttg ggcactctag 1140
taagactgcc ggtgacaaac cggaggaagg tggggatgac gtcaaatcat catgcccctt 1200
atgacctggg ctacacacgt gctacaatgg atggtacaac gagttgcgag accgcgaggt 1260
caagctaatc tcttaaagcc attctcagtt cggactgtag gctgcaactc gcctacacga 1320
agtcggaatc gctagtaatc gcggatcagc acgccgcggt gaatacgttc ccgggccttg 1380
tacacaccgc ccgtcacacc atgagagttt gtaacacccg aagccggtgg cgtaaccctt 1440
ttagggagcg agccgtctaa ggtgaacaaa a 1471
Claims (6)
1.鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX-01在制备防治高温引起的人或哺乳动物的疾病的产品中的应用,所述鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX-01保藏于广东省微生物菌种保藏中心,保藏编号为GDMCCNo:60986,所述高温引起的疾病为热应激或全身性炎症。
2.鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX-01的培养物在制备防治高温引起的人或哺乳动物的疾病的产品中的应用,所述鼠李糖乳杆菌(Lactobacillus rhamnosus)LRX-01保藏于广东省微生物菌种保藏中心,保藏编号为GDMCC No:60986,所述高温引起的疾病为热应激或全身性炎症。
3.根据权利要求1或2所述的应用,其特征在于,所述产品为药品、菌剂或饲料添加剂。
4.根据权利要求3所述的应用,其特征在于,所述药品还包括药学上可接受的辅剂。
5.根据权利要求4所述的应用,其特征在于,所述辅剂为稳定剂、湿润剂、乳化剂、粘合剂、等渗剂中的一种或几种。
6.根据权利要求5所述的应用,其特征在于,所述药品的剂型为片剂、颗粒剂、散剂、胶囊剂、溶液剂、悬浮剂、或冻干制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111449823.9A CN114231446B (zh) | 2021-11-30 | 2021-11-30 | 鼠李糖乳杆菌lrx-01的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111449823.9A CN114231446B (zh) | 2021-11-30 | 2021-11-30 | 鼠李糖乳杆菌lrx-01的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114231446A CN114231446A (zh) | 2022-03-25 |
CN114231446B true CN114231446B (zh) | 2023-05-05 |
Family
ID=80752310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111449823.9A Active CN114231446B (zh) | 2021-11-30 | 2021-11-30 | 鼠李糖乳杆菌lrx-01的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114231446B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114561313B (zh) * | 2021-08-26 | 2022-09-13 | 佛山市孛特碧欧微生物科技有限公司 | 格氏乳杆菌及其应用 |
CN115927106B (zh) * | 2022-12-16 | 2023-09-08 | 南方医科大学南方医院 | 一株鼠李糖乳酪杆菌dy801及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014033307A1 (en) * | 2012-08-31 | 2014-03-06 | University College Cork - National University Of Ireland, Cork | Exopolysaccharide-producing bacteria, and uses thereof for protecting heart health |
AT515336A1 (de) * | 2014-02-03 | 2015-08-15 | Roth Hermann Dr | Vermeidung oxidativer Prozesse und oxidativem Stress |
CN110122877B (zh) * | 2018-02-09 | 2022-12-23 | 深圳华大基因农业控股有限公司 | 鼠李糖乳杆菌及其用途 |
CN112322528B (zh) * | 2020-11-03 | 2022-07-22 | 江南大学 | 一株可干预代谢综合征的鼠李糖乳杆菌及应用 |
-
2021
- 2021-11-30 CN CN202111449823.9A patent/CN114231446B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN114231446A (zh) | 2022-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2750070C (en) | Method for alleviating intestinal problems and novel bacterial strains therefor | |
WO2019085521A1 (zh) | 一种具有抑制结直肠癌发生功能的植物乳杆菌及其用途 | |
CN114231446B (zh) | 鼠李糖乳杆菌lrx-01的应用 | |
CN113832077B (zh) | 鼠李糖乳杆菌及其应用 | |
CN110452842B (zh) | 乳双歧杆菌nbk-W13及其应用 | |
CN110591945A (zh) | 一株用于预防溃疡性结肠炎的优良罗伊氏乳杆菌 | |
CN112218646B (zh) | 一种组合物及其应用 | |
CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
CN114854638B (zh) | 一株高效表达腺苷脱氨酶mRNA缓解结肠炎副干酪乳杆菌 | |
CN117143766A (zh) | 一株修复肠神经的副干酪乳杆菌及其应用 | |
CN117025489B (zh) | 一种动物双歧杆菌乳亚种vb315及其应用 | |
CN112940984B (zh) | 抗幽门螺杆菌、降血糖、调理肠胃和增加免疫力的复合乳酸杆菌制剂及其制备方法 | |
US20230346856A1 (en) | Bifidobacterium brevis and its application in preventing or alleviating psoriasis thereof | |
CN117004503B (zh) | 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用 | |
CN117143765A (zh) | 一株调控肠道稳态缓解顽固性便秘的长双歧杆菌长亚种及其应用 | |
CN115737689B (zh) | 乳酸杆菌在制备预防和治疗炎症性肠病的药物中的应用 | |
CN115992059B (zh) | 一株产阿魏酸酯酶的约氏乳杆菌及其缓解溃疡性结肠炎的用途 | |
WO2021169627A1 (zh) | Blautia sp B2132菌在预防和/或治疗炎症性肠病中的应用 | |
CN112980736A (zh) | 一种能增加调理肠胃功能效果的干酪乳杆菌制剂及其制备方法 | |
CN112961808A (zh) | 一种降脂减肥的乳双岐杆菌制剂及其制备方法 | |
CN116496938B (zh) | 一株产透明质酸的嗜酸乳杆菌my2及其在制备抗衰老和美白食品药品中的应用 | |
CN112236155A (zh) | 一种组合物及其应用 | |
CN115029270B (zh) | 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用 | |
CN118086155B (zh) | 一株具有减肥降脂功效的发酵粘液乳杆菌un-p及其应用 | |
CN113699079B (zh) | 一株具有缓解腹泻和促生长作用的多形拟杆菌lyh5及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221118 Address after: 528200 Room 3, 2714, Building 2, South China International Financial Center, No. 28, Haiwu Road, Guicheng Street, Nanhai District, Foshan City, Guangdong Province Applicant after: Foshan Bote Biou Microbial Technology Co.,Ltd. Address before: 510630 No. 1023-1063, shatai South Road, Tianhe District, Guangzhou, Guangdong Applicant before: SOUTHERN MEDICAL University Applicant before: GUANGZHOU WEISHENGJUN BIOTECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |